Reply To: Avacta

Nick Hargrave

An excellent move by the company. Christina has clearly impressed and added value to the clinical strategy, perhaps responsible for the AVA6000 study re-design and overall acceleration of the FDA approvals. Obviously Christina has decided she wants to be ‘in’ rather than just a temporary consultant. The company has allowed, by its standards, quite incendiary language for them about the next frontier of oncology and game-changing platform, just as the company is expected to start announcing commercial deals